Hubei Keyi Pharmaceutical Co., Ltd.

Hubei Keyi Pharmaceutical Co., Ltd. is a key high-tech enterprise under the National Torch Program, a high-tech enterprise and a key pharmaceutical technology enterprise recognized by the Hubei Provincial Department of Science and Technology, and a key high-tech enterprise recognized by the Wuhan East Lake National New Technology Development Zone.
Keyi Company is currently a key enterprise in the industrialization of antiviral drugs in China, integrating scientific research, production and operation. Over the years, it has developed new drug achievements such as ganciclovir, ribavirin, acyclovir, penciclovir, valacyclovir, imiquimod and others that have generated good social and economic benefits, driving the increasingly active national antiviral drug market and promoting the optimization and upgrading of China's pharmaceutical industry structure and product structure adjustment. The synthesis and preparation process of the leading product ganciclovir has completely independent intellectual property rights and won the second prize of the National Science and Technology Progress Award. It has been listed successively as a National Torch Program project, a National Technology Innovation Fund project, and a National Key New Product Plan project, and has been recognized as a Hubei Famous Brand Product for two consecutive sessions.
The company has strong scientific research strength and a complete scientific research system, with research institutions for drug synthesis, natural medicines, pharmaceutical preparations, pharmaceutical engineering, and pharmaceutical information. The direction of new drug research and development focuses on the fields of antiviral drugs and anti-infective drugs, mainly chemical drugs, traditional Chinese medicines and natural medicines, and new drug preparations.
The company has established a high-quality marketing team with medical professional backgrounds and rich marketing experience. It adopts a knowledge marketing model led by academic promotion, which has expanded the visibility of new products and established a good corporate social image and product brand reputation. At present, it has established a marketing network covering all provinces and cities across the country.
The company has established a new drug industrialization base that meets national GMP standards. Major dosage forms such as chemical APIs, lyophilized powder injections, oral solid preparations, and ointments have formed large-scale production capacity. The rationally laid out and tidy production plant environment, various advanced automated production equipment, and a complete product quality assurance system and other basic hardware have effectively promoted the improvement of product quality.
The company adheres to the path of pharmaceutical specialization, is market-oriented, relies on scientific and technological progress, is committed to independent technological innovation, and carefully builds core competitiveness. It gives full play to its competitive advantages in the national antiviral drug field, and based on a high-quality asset structure, good operating performance, excellent profitability and potential high growth, strives to achieve the strategic goal of becoming stronger and larger, and make greater contributions to the development of the health cause of the Chinese people.
:*******************